JP2009523141A - トリアジン誘導体およびHMG−CoAレダクターゼ阻害剤の組合せ - Google Patents

トリアジン誘導体およびHMG−CoAレダクターゼ阻害剤の組合せ Download PDF

Info

Publication number
JP2009523141A
JP2009523141A JP2008549782A JP2008549782A JP2009523141A JP 2009523141 A JP2009523141 A JP 2009523141A JP 2008549782 A JP2008549782 A JP 2008549782A JP 2008549782 A JP2008549782 A JP 2008549782A JP 2009523141 A JP2009523141 A JP 2009523141A
Authority
JP
Japan
Prior art keywords
alkoxy
alkyl
amino
aryl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008549782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523141A5 (cg-RX-API-DMAC10.html
Inventor
ジェラール モワネ、
ダニエル クラヴォ、
ディディエ メサンジョ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2009523141A publication Critical patent/JP2009523141A/ja
Publication of JP2009523141A5 publication Critical patent/JP2009523141A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2008549782A 2006-01-13 2006-12-18 トリアジン誘導体およびHMG−CoAレダクターゼ阻害剤の組合せ Pending JP2009523141A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600343A FR2896158B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
PCT/EP2006/012184 WO2007079916A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes

Publications (2)

Publication Number Publication Date
JP2009523141A true JP2009523141A (ja) 2009-06-18
JP2009523141A5 JP2009523141A5 (cg-RX-API-DMAC10.html) 2010-02-12

Family

ID=36649749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008549782A Pending JP2009523141A (ja) 2006-01-13 2006-12-18 トリアジン誘導体およびHMG−CoAレダクターゼ阻害剤の組合せ

Country Status (14)

Country Link
US (1) US20100158999A1 (cg-RX-API-DMAC10.html)
EP (1) EP1978951A2 (cg-RX-API-DMAC10.html)
JP (1) JP2009523141A (cg-RX-API-DMAC10.html)
KR (1) KR20080085208A (cg-RX-API-DMAC10.html)
CN (1) CN101355935A (cg-RX-API-DMAC10.html)
AR (1) AR059031A1 (cg-RX-API-DMAC10.html)
AU (1) AU2006334733A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0621420A2 (cg-RX-API-DMAC10.html)
CA (1) CA2636840A1 (cg-RX-API-DMAC10.html)
EA (1) EA200801666A1 (cg-RX-API-DMAC10.html)
FR (1) FR2896158B1 (cg-RX-API-DMAC10.html)
IL (1) IL192594A0 (cg-RX-API-DMAC10.html)
WO (1) WO2007079916A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806937B (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021117861A1 (ja) * 2019-12-13 2021-06-17 大日本住友製薬株式会社 製造性及び溶出性に優れた小型錠剤
JP2021526506A (ja) * 2018-06-14 2021-10-07 ポクセルPoxel 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US8722674B2 (en) 2007-08-31 2014-05-13 Hanall Biopharma Co., Ltd. 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same
JP5485292B2 (ja) * 2008-12-12 2014-05-07 ポクセル・エスアーエス Ampk活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0971540A (ja) * 1995-07-03 1997-03-18 Sankyo Co Ltd 動脈硬化症予防および治療剤
JP2003520858A (ja) * 2000-01-26 2003-07-08 リファ ジヒドロ−1,3,5−トリアジンのアミン含有誘導体およびそれらの治療用用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0971540A (ja) * 1995-07-03 1997-03-18 Sankyo Co Ltd 動脈硬化症予防および治療剤
JP2003520858A (ja) * 2000-01-26 2003-07-08 リファ ジヒドロ−1,3,5−トリアジンのアミン含有誘導体およびそれらの治療用用途

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526506A (ja) * 2018-06-14 2021-10-07 ポクセルPoxel 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤
JP7266616B2 (ja) 2018-06-14 2023-04-28 ポクセル 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤
WO2021117861A1 (ja) * 2019-12-13 2021-06-17 大日本住友製薬株式会社 製造性及び溶出性に優れた小型錠剤
JPWO2021117861A1 (cg-RX-API-DMAC10.html) * 2019-12-13 2021-06-17
JP7093473B2 (ja) 2019-12-13 2022-06-29 住友ファーマ株式会社 製造性及び溶出性に優れた小型錠剤
JP2022123069A (ja) * 2019-12-13 2022-08-23 住友ファーマ株式会社 製造性及び溶出性に優れた小型錠剤
JP7671265B2 (ja) 2019-12-13 2025-05-01 住友ファーマ株式会社 製造性及び溶出性に優れた小型錠剤

Also Published As

Publication number Publication date
CN101355935A (zh) 2009-01-28
AU2006334733A1 (en) 2007-07-19
FR2896158B1 (fr) 2008-09-12
WO2007079916A3 (en) 2007-12-06
CA2636840A1 (en) 2007-07-19
FR2896158A1 (fr) 2007-07-20
EA200801666A1 (ru) 2008-12-30
US20100158999A1 (en) 2010-06-24
WO2007079916A2 (en) 2007-07-19
ZA200806937B (en) 2009-07-29
BRPI0621420A2 (pt) 2011-12-06
AR059031A1 (es) 2008-03-12
IL192594A0 (en) 2009-09-22
KR20080085208A (ko) 2008-09-23
EP1978951A2 (en) 2008-10-15

Similar Documents

Publication Publication Date Title
EP3925959A1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
US20140050786A1 (en) Combination of triazine derivatives and insulin sensitisers
JP5702911B2 (ja) トリアジン誘導体およびインスリン分泌促進剤の組合せ
US20100158999A1 (en) Combination of triazine derivatives and hmg-coa reductase inhibitors
MX2008008887A (en) Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes
JP2009523143A (ja) トリアジン誘導体およびPPARα作動薬の組合せ
HK1128231A (en) Combination of triazine derivatives and hmg-coa reductase inhibitors for the treatment of diabetes
HK1128233A (en) COMBINATION OF TRIAZINE DERIVATIVES AND PPARα AGONISTS
MX2008008894A (en) Combination of triazine derivatives and insulin secretion stimulators
HK1128232A (en) Combination of triazine derivatives and insulin sensitisers
MX2008008895A (en) Combination of triazine derivatives and insulin sensitisers
HK1128405A (en) Combination of triazine derivatives and insulin secretion stimulators

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121106